Ulocuplumab (Anti-CXCR4 / CD184)

Ask supplier a question | View on supplier's website

Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.

Supplier	Selleck Chemicals
Product #	A2523
Sku #	A2523-1mg*25
Pricing	1mg*25, $2370.00

Feedback